前列地尔联合厄贝沙坦治疗慢性肾小球肾炎的疗效观察

Observation on Efficacy of Alprostadil Combined with Irbesartan in Treatment of Chronic Glomerulonephritis

目的:探讨前列地尔联合厄贝沙坦治疗慢性肾小球肾炎的临床疗效。方法:选取2016年4月至2017年10月湖北文理学院附属谷城医院收治的慢性肾小球肾炎患者80例,根据随机数字表法分为观察组和对照组,每组40例。对照组患者给予厄贝沙坦治疗,观察组患者给予前列地尔联合厄贝沙坦治疗。比较两组患者的血清肌酐(SCr)、尿素氮(BUN)、24 h尿蛋白定量水平、临床疗效及不良反应发生情况的差异。结果:治疗后,观察组患者Scr、BUN及24 h尿蛋白定量水平明显低于对照组,差异均有统计学意义(P<0.05);观察组患者的总有效率为92.50%(37/40),明显高于对照组的77.50%(31/40),差异有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为5.00%(2/40)、2.50%(1/40),差异无统计学意义(P>0.05)。结论:前列地尔联合厄贝沙坦治疗慢性肾小球肾炎可提高疗效,显著改善患者的肾功能,且安全性高。

OBJECTIVE:To probe into the clinical efficacy of alprostadil combined with irbesartan in treatment of chronic glomerulonephritis. METHODS:80 patients chronic glomerulonephritis admitted into Gucheng Hospital Affiliated to Hubei University of Arts and Sciences from Apr. 2016 to Oct. 2017 were extracted to be divided into observation group and control group via the random number table, with 40 cases in each. Patients in the control group were treated with irbesartan, while the observation group were given prostaglandil combined with irbesartan. Differences of serum creatinine(SCr), blood urea nitrogen(BUN), 24-hour urine protein quantitation, clinical efficacy and adverse drug reactions were compared between two groups. RESULTS:After treatment, the levels of Scr, BUN and 24 h urine protein in observation group were significantly lower than those in control group, and the differences were statistically significant(P<0.05). The total effective rate of observation group was 92.50%(37/40), significantly higher than that of control group(77.50%, 31/40), the difference was statistically significant(P<0.05). The incidences of adverse drug reactions in the observation group and the control group were 5.00%(2/40) and 2.50%(1/40), respectively, the difference was not statistically significant(P>0.05). CONCLUSIONS:Alprostadil combined with irbesartan in treatment of chronic glomerulonephritis can promote the efficacy, and significantly improve the renal function of patients with higher safety.